Florian Heidel

Has grant

Professor, Director

Universitätsmedizin Greifswald

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Florian Heidel is a Professor and Director at Universitätsmedizin Greifswald, Germany. His research focuses on myeloid cancers, particularly the role of epigenetic therapies in acute myeloid leukemia and myeloproliferative neoplasms. He has published several articles discussing the implications of JAK-signaling pathways, resistance mechanisms in polycythemia vera, and the therapeutic potential of CAR-T cell therapy.

Recent Grants

Grant: Close

Functional characterization of histone replacement variant MacroH2A1 (H2afy) in acute myeloid leukemia (AML)

Open Date: 2022-01-01

Close Date:

Grant: Close

Meeting the Challenges of Chronic Age-Related Diseases in Rural Areas

Open Date: 2022-01-01

Close Date:

Grant: Close

Effects of YBX1 on gene expression and translation in acute myeloid leukemia (AML)

Open Date: 2020-01-01

Close Date:

Grant: Close

Mechanistic impact of immunoproteasome function on cell competition in acute myeloid leukemia (AML)

Open Date: 2020-01-01

Close Date:

Grant: Close

Impact of Plcg1 on hematopoietic and leukemia stem cell function

Open Date: 2017-01-01

Close Date:

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (20)

daniela cilloni

PROFESSOR

University of Turin

ITALY

Florian Heidel

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms

Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM)

Malignant JAK-signaling: at the interface of inflammation and malignant transformation

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)

Pomalidomide combinations are a safe and effective option after daratumumab failure

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.

Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis

Aggregates of non-muscular myosin IIA in erythrocytes associate with GATA1- and GFI1B-related thrombocytopenia.

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.

Breakthrough infections in MPN-COVID vaccinated patients.

Dynamic DNA methylation reveals novel cis-regulatory elements in mouse hematopoiesis.

Taz protects hematopoietic stem cells from an aging-dependent decrease in PU.1 activity.

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.

Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms.

Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.

Collaborators (20)

daniela cilloni

Alejo Rodriguez-Fraticelli

Elisabetta Abruzzese

Antonio Cuneo

Annamaria Brioli

Francesco Ferracuti

Thomas Stoll

Inken Hilgendorf

Yee-May Ling

Valerio De Stefano

Massimiliano BONIFACIO

Steven Lane

Mascha Binder

Giuseppe Alberto Maria PALUMBO

José Rivera

Claudia Bruedigam

Gunter Hartel

Steffen Koschmieder

Giovanni Caocci

Gerald de Haan

Make your next move.